Themis Medicare Q2 FY26: Revenue ₹77.99 Cr, Net loss ₹3.62 Cr
Q2 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹78Cr
- −33.3% YoY
- −20.1% QoQ
- Net profit
- −₹4Cr
- Q2 FY25: ₹14 Cr
- Margin
- −3.97%
- −18.6 pp YoY
- +6.5 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Themis Medicare Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY26 Net Revenue: ₹77.99 Cr, down 33.3% YoY from ₹117.01 Cr in Q2 FY25 (Page 8) - H1 FY26 Net Revenue: ₹175.57 Cr, down 26.8% YoY from ₹240.0 Cr in H1 FY25 (Page 9) - API business showed growth in Quarter (Q2 FY26) Financials vs Q2 FY25: - EBITDA: ₹(3.09) Cr, down 118.0% YoY (Q2 FY25: ₹17.13 Cr) - EBITDA Margin: (3.96)%, down from 14.6% YoY - PAT: ₹(3.62) Cr, down 125.3% YoY (Q2 FY25: ₹14.29 Cr) - PAT Margin: (4.64)%, down from 12.2% YoY - Operating Margin: - EBITDA margin for Q2 FY26 is negative at (3.96)%.
From Themis Medicare Ltd's Q2 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q2 FY26 Net Revenue: ₹77.99 Cr, down 33.3% YoY from ₹117.01 Cr in Q2 FY25 (Page 8)
- H1 FY26 Net Revenue: ₹175.57 Cr, down 26.8% YoY from ₹240.0 Cr in H1 FY25 (Page 9)
- API business showed growth in the half year with a 31% YoY increase; Trade business increased 4% (Page 5)
- Formulations business faced headwinds negatively impacting top line (Page 8)
- Management expects positive regulatory developments by March 2026 (Page 5)
2 more points from Themis Medicare Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Themis Medicare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Themis Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Themis Medicare Ltd — Quarterly revenue & net profit
Themis Medicare Ltd Q2 FY26 results — key figures
| ₹ Cr | Q2 FY26 |
|---|---|
| Revenue | 78 |
| Operating profit (EBITDA) | -3 |
| Operating margin | -4% |
| Profit before tax | -5 |
| Net profit (PAT) | -4 |
| EPS (₹) | -0.39 |
Source: Themis Medicare Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹90 Cr, net profit ₹7 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Themis Medicare's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Themis Medicare Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Themis Medicare Ltd Q2 FY26 results?
Q2 FY26 Net Revenue: ₹77.99 Cr, down 33.3% YoY from ₹117.01 Cr in Q2 FY25 (Page 8) - H1 FY26 Net Revenue: ₹175.57 Cr, down 26.8% YoY from ₹240.0 Cr in H1 FY25 (Page 9) - API business showed growth in Quarter (Q2 FY26) Financials vs Q2 FY25: - EBITDA: ₹(3.09) Cr, down 118.0% YoY (Q2 FY25: ₹17.13 Cr) - EBITDA Margin: (3.96)%, down from 14.6% YoY - PAT: ₹(3.62) Cr, down 125.3% YoY (Q2 FY25: ₹14.29 Cr) - PAT Margin: (4.64)%, down from 12.2% YoY - Operating Margin: - EBITDA margin for Q2 FY26 is negative at (3.96)%.
What is Themis Medicare Ltd share price analysis?
Themis Medicare Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,142 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Themis Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
